Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The company specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
The Grindeks’ Group consists of 5 subsidiary companies in Latvia, Estonia, Russia and Slovakia; representative offices are opened in 13 countries.
Grindeks’ products are exported to 70 countries with export comprising 90% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam. Company’s shares are listed on the Official List of Nasdaq Riga.
Sold in 70 countries worldwide, Grindeks’ product portfolio is successfully composed of branded products, generic medications and active pharmaceutical ingredients, all produced in line with the world class requirements of safety and quality.
Grindeks is a worldwide Active Pharmaceutical Ingredients (APIs) supplier due to quality, modern manufacturing units and global regulatory accreditation. APIs are produced according to GMP requirements, certified by Authorization (licence) for API manufacturing and Certificate of GMP compliance of manufacturer.
AS Grindeks (branded as Grindex), is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.
One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate. Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.
In 2015, Grindeks had a turnover revenue of €82.7 million with a profit of €1.0 million. Grindeks had 883 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anna Lipmane (16.65%).